Stock REPROS THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Repros Therapeutics Inc

Equities

US76028H2094

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Repros Announces Negative Opinion From the EMA for Enclomiphene
GL
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
GL
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
GL
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
GL
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results
GL
Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
GL
Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock
GL
Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
GL
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results
GL
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
GL
Repros Names Larry Dillaha, M.D., its Permanent President and CEO
GL
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids
GL
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
GL
Repros Announces New CEO
GL
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
GL
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
GL
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids
GL
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
GL
Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids
GL
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Repros Therapeutics Inc